Arbutus Biopharma Corp
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious disease, with its current development efforts centered on chronic hepatitis B. The company’s lead internal programs are imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered RNAi therapeutic, and AB-101, an oral PD-L1 inhibitor. In addition to drug development, Arbutus monetizes parts of its intellectual property and delivery technology through collaborations, licenses, and royalty interests. Its business model combines early-stage therapeutic development with technology licensing and royalty income, which helps offset the cash demands of clinical research.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueInternal drug candidates in development for chronic hepatitis B, including imdusiran and AB-101.
Upfront, milestone, and performance-based revenue from partner agreements such as Qilu and other licensing arrangements.
Ongoing royalty revenue from ONPATTRO sales and other royalty interests retained by the company.
Licensing of Arbutus-owned LNP and ligand conjugate delivery technologies to third parties outside HBV.
Products
Reported · share of revenue- Collaboration and Contracts89.5 %
- Non Cash Royalty10.5 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Arbutus does not sell commercial medicines directly to patients; its economic customers are pharmaceutical partners and licensees. The most visible partner disclosed in recent filings is Qilu Pharmaceutical, which is responsible for development, regulatory approval, and commercialization of imdusiran in Greater China and Taiwan. The company also receives royalty revenue tied to ONPATTRO sales, reflecting an economic relationship with the commercial success of partnered products rather than direct end-market sales. More broadly, its counterparties are biopharma companies that value Arbutus’s HBV programs, RNAi know-how, and delivery technology for use in their own development pipelines.
Companies like Qilu that fund development, regulatory work, and commercialization of partnered assets in defined territories.
Commercial product owners whose sales, such as ONPATTRO, generate ongoing royalty income for Arbutus.
Biopharma companies that license Arbutus's LNP and ligand conjugate delivery platforms for non-HBV applications.
Third parties that may commercialize products through Genevant-related sublicenses and revenue-sharing structures.
Strategy
Arbutus’s current strategy is to maximize the value of its chronic hepatitis B programs while preserving cash and focusing resources on the most promising assets. Management has streamlined the organization, discontinued discovery work, halted the IM-PROVE III trial, reduced headcount, and exited its headquarters to lower burn and concentrate on imdusiran and AB-101. The company is also trying to monetize its in-house LNP delivery technology through licensing and revenue-sharing structures, which can create value without requiring full commercial buildout. This strategy reflects a capital-efficient model in which partner funding and royalty streams support a smaller internal R&D base.
These are the company’s core internal assets and the main source of long-term therapeutic value.
The company remains clinical-stage and needs to preserve liquidity while development timelines remain uncertain.
Licensing the LNP platform can generate non-dilutive value from assets outside the core HBV focus.
Geography
Arbutus is headquartered in the United States, and its operating footprint is shaped by where its partners develop and commercialize products rather than by a large commercial manufacturing network. The clearest geographic exposure in the filings is Greater China and Taiwan through the Qilu arrangement for imdusiran. The company also has economic exposure to global ONPATTRO sales through royalty interests, which makes its revenue partly dependent on worldwide commercial performance. In 2025, Arbutus also exited its Warminster, Pennsylvania headquarters as part of a restructuring, underscoring a leaner operating model centered on partner-led development.
Risks
Arbutus faces the typical risks of a clinical-stage biopharma company: clinical failure, regulatory setbacks, and long development timelines before any product can generate meaningful commercial revenue. Its dependence on a small number of programs makes execution risk high, especially because imdusiran and AB-101 are still in development and the company has already narrowed its pipeline. Revenue is also volatile because a meaningful portion comes from royalties and collaboration accounting, which can fluctuate with partner sales and milestone recognition. In addition, the company is exposed to patent and licensing disputes around its LNP portfolio, and any adverse outcome could weaken future licensing leverage or royalty economics.
The company’s value is concentrated in two HBV programs, so weak data or slow enrollment would materially impair prospects.
Exposure: Lead pipeline assets
Arbutus’s licensing and royalty leverage depends on enforceable intellectual property, and opponents have challenged key patents.
Exposure: LNP technology and Genevant-related licensing
As a clinical-stage company, Arbutus depends on external funding, partner receipts, and royalty income to support operations.
Exposure: Corporate cash runway
A large share of revenue comes from a small number of collaboration and royalty sources, making results sensitive to partner performance.
Exposure: ONPATTRO royalties and Qilu-related revenue
Accounting
Judgemental itemsRevenue is recognized as obligations are satisfied, so timing of development and technology transfer work materially affects reported results.
Impact: Can create lumpy quarterly revenue and deferred revenue balances
ONPATTRO-related income depends on partner sales and includes non-cash elements, making revenue sensitive to external commercial performance.
Impact: Affects revenue volatility and comparability across periods
Workforce reductions and headquarters exit actions can generate one-time charges and accrual estimates.
Impact: Can materially affect operating expenses in the period incurred
Similar listed companies
Publicly listed companies with a comparable business focus.
Arcus Biosciences, Inc.
RCUS · Pharmaceutical Preparations
Arcus Biosciences is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and, to a lesser extent, inflammatory and autoimmune diseases.
Arrowhead Pharmaceuticals, Inc
ARWR · Pharmaceutical Preparations
Arrowhead Pharmaceuticals is a U.S.-based biopharmaceutical company focused on developing RNA interference medicines that silence disease-causing genes.
Barinthus Biotherapeutics plc.
BRNS · Pharmaceutical Preparations
Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company built around immune-modulating platforms rather than marketed drugs.
Connect Biopharma Holdings Ltd
CNTB · Pharmaceutical Preparations
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company focused on developing rademikibart, an antibody designed to target IL-4Rα for asthma and COPD.
Arvinas, Inc
ARVN · Pharmaceutical Preparations
Propanc Biopharma, Inc.
PPCB · Pharmaceutical Preparations
Last updated: 24/09/2026